The Relationship among Pore-Size Ratings, Bubble Points, and Porosity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Relationship among Pore-Size Ratings, Bubble Points, and Porosity


Pharmaceutical Technology


35. EMEA CPMP/QMP/489/95, Note For Guidance in Manufacture of the Finished Dosage Form, 5-6 (April reissue 1996).

36. J.P. Agalloco, "Guest Editorial: It Just Doesn't Matter," PDA J. Pharm. Sci. Technol. 52 (4), 149–150 (1998).

37. Society of Automotive Engineers (SAE), Bubble Point Test. Method, Aerospace Recommended Practice ARP-901 (1968).

38. M.W. Jornitz and T.H. Meltzer, Filtration Handbook: Integrity Testing (PDA, Bethesda, MD; DHI Publishing, River Grove, IL, 2003).

39. D.B. Pall, "Quality Control of Absolute Bacteria Removal Filters," Bull. PDA 29, 192–212 (1975).

40. A. Baszkin, D.J. Lyman, and T.H. Meltzer, "Theoretical Considerations of BubblePoint Measurement: Solid/Liquid Wetting Interaction," Pharm. Technol. Int. 2 (l), 22–31 (1978).

41. P.R. Johnston and T.H. Meltzer, "Comments on Organism Challenge Levels in Sterilizing-Filter Efficiency Testing," Pharm. Technol. 3 (11), 66–70, 110 (1979).

42. W.J. Elford, "The Principles of Ultrafiltration as Applied in Biological Studies," Proceedings of the Royal Society, 112B (London, UK, 1933), pp. 384–406.

43. A.R. Reti, "An Assessment of Test Criteria in Evaluating the Performance and Integrity of Sterilizing Filters," Bull. Paren Drug Assoc. 3l (4), 187–194 (1977).

44. D.C. Grant and J.G. Zahke, "Sieving Capture of Particles by MicroporousMembrane Filters From Clean Liquids," Swiss Contamin. Control 3 (4a), 160–164 (1990).

45. M.L. Roberts and D.J. Valazquez, "Characterizing the Rating and Performance of Membrane Filter for Liquid Applications Using Latex Spheres," Swiss Contam. Quarterly 3, 71–74 (1990).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here